Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.

Hofving T, Sandblom V, Arvidsson Y, Shubbar E, Altiparmak G, Swanpalmer J, Almobarak B, Elf AK, Johanson V, Elias E, Kristiansson E, Forssell-Aronsson E, Nilsson O.

Endocr Relat Cancer. 2019 Apr 1;26(4):437-449. doi: 10.1530/ERC-18-0509. Epub 2019 Feb 1.

2.

The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.

Hofving T, Arvidsson Y, Almobarak B, Inge L, Pfragner R, Persson M, Stenman G, Kristiansson E, Johanson V, Nilsson O.

Endocr Relat Cancer. 2018 Apr;25(4):X1-X2. doi: 10.1530/ERC-17-0445e. No abstract available.

PMID:
29540494
3.

miRNA profiling of small intestinal neuroendocrine tumors defines novel molecular subtypes and identifies miR-375 as a biomarker of patient survival.

Arvidsson Y, Rehammar A, Bergström A, Andersson E, Altiparmak G, Swärd C, Wängberg B, Kristiansson E, Nilsson O.

Mod Pathol. 2018 Aug;31(8):1302-1317. doi: 10.1038/s41379-018-0010-1. Epub 2018 Feb 27.

PMID:
29487354
4.

The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.

Hofving T, Arvidsson Y, Almobarak B, Inge L, Pfragner R, Persson M, Stenman G, Kristiansson E, Johanson V, Nilsson O.

Endocr Relat Cancer. 2018 Mar;25(3):367-380. doi: 10.1530/ERC-17-0445. Erratum in: Endocr Relat Cancer. 2018 Apr;25(4):X1-X2.

5.

Priming increases the anti-tumor effect and therapeutic window of 177Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1.

Dalmo J, Spetz J, Montelius M, Langen B, Arvidsson Y, Johansson H, Parris TZ, Helou K, Wängberg B, Nilsson O, Ljungberg M, Forssell-Aronsson E.

EJNMMI Res. 2017 Dec;7(1):6. doi: 10.1186/s13550-016-0247-y. Epub 2017 Jan 5.

6.

NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors.

Elf AK, Bernhardt P, Hofving T, Arvidsson Y, Forssell-Aronsson E, Wängberg B, Nilsson O, Johanson V.

J Nucl Med. 2017 Feb;58(2):288-292. doi: 10.2967/jnumed.116.177584. Epub 2016 Sep 29.

7.

Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets.

Andersson E, Arvidsson Y, Swärd C, Hofving T, Wängberg B, Kristiansson E, Nilsson O.

Mod Pathol. 2016 Jun;29(6):616-29. doi: 10.1038/modpathol.2016.48. Epub 2016 Mar 11.

8.

Cytotoxic Effects of Valproic Acid on Neuroendocrine Tumour Cells.

Arvidsson Y, Johanson V, Pfragner R, Wängberg B, Nilsson O.

Neuroendocrinology. 2016;103(5):578-91. doi: 10.1159/000441849. Epub 2015 Oct 28.

PMID:
26505883
9.

Gastrointestinal stromal tumors (GISTs) express somatostatin receptors and bind radiolabeled somatostatin analogs.

Arne G, Nilsson B, Dalmo J, Kristiansson E, Arvidsson Y, Forssell-Aronsson E, Nilsson O, Ahlman H.

Acta Oncol. 2013 May;52(4):783-92. doi: 10.3109/0284186X.2012.733075. Epub 2012 Nov 1.

PMID:
23116418
10.

New medical strategies for midgut carcinoids.

Nilsson O, Arvidsson Y, Johanson V, Forssell-Aronsson E, Ahlman H.

Anticancer Agents Med Chem. 2010 Mar;10(3):250-69. Review.

PMID:
20406194
11.

Hypoxia stimulates CXCR4 signalling in ileal carcinoids.

Arvidsson Y, Bergström A, Arvidsson L, Kristiansson E, Ahlman H, Nilsson O.

Endocr Relat Cancer. 2010 Jun 1;17(2):303-16. doi: 10.1677/ERC-09-0085. Print 2010 Jun.

PMID:
20071457
12.

The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response.

Andersson MK, Ståhlberg A, Arvidsson Y, Olofsson A, Semb H, Stenman G, Nilsson O, Aman P.

BMC Cell Biol. 2008 Jul 11;9:37. doi: 10.1186/1471-2121-9-37.

13.

Amyloid precursor-like protein 1 is differentially upregulated in neuroendocrine tumours of the gastrointestinal tract.

Arvidsson Y, Andersson E, Bergström A, Andersson MK, Altiparmak G, Illerskog AC, Ahlman H, Lamazhapova D, Nilsson O.

Endocr Relat Cancer. 2008 Jun;15(2):569-81. doi: 10.1677/ERC-07-0145. Epub 2008 Apr 22.

PMID:
18430897
14.

A novel MASH1 enhancer with N-myc and CREB-binding sites is active in neuroblastoma.

Watt F, Watanabe R, Yang W, Agren N, Arvidsson Y, Funa K.

Cancer Gene Ther. 2007 Mar;14(3):287-96. Epub 2006 Nov 24.

PMID:
17124508
15.

Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice.

Johanson V, Arvidsson Y, Kölby L, Bernhardt P, Swärd C, Nilsson O, Ahlman H.

Neuroendocrinology. 2005;82(3-4):171-6. Epub 2006 Feb 24.

PMID:
16508338
16.

Neuroblastoma-specific cytotoxicity mediated by the Mash1-promoter and E. coli purine nucleoside phosphorylase.

Arvidsson Y, Sumantran V, Watt F, Uramoto H, Funa K.

Pediatr Blood Cancer. 2005 Jan;44(1):77-84.

PMID:
15390277
17.
18.

Nuclear accumulation of full-length and truncated adenomatous polyposis coli protein in tumor cells depends on proliferation.

Fagman H, Larsson F, Arvidsson Y, Meuller J, Nordling M, Martinsson T, Helmbrecht K, Brabant G, Nilsson M.

Oncogene. 2003 Sep 4;22(38):6013-22.

PMID:
12955080
19.

ASK1 resistant neuroblastoma is deficient in activation of p38 kinase.

Arvidsson Y, Hamazaki TS, Ichijo H, Funa K.

Cell Death Differ. 2001 Oct;8(10):1029-37.

20.

Reduction of ribulose-1,5-bisphosphate carboxylase/oxygenase content by antisense RNA reduces photosynthesis in transgenic tobacco plants.

Hudson GS, Evans JR, von Caemmerer S, Arvidsson YB, Andrews TJ.

Plant Physiol. 1992 Jan;98(1):294-302.

Supplemental Content

Loading ...
Support Center